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Abstract
Background: Post-kala-azar dermal leishmaniasis (PKDL) is a dermal complication of visceral leishmaniasis (VL),
which may occur after or during treatment. It has been frequently reported from India and the Sudan, but its
occurrence in South America has been rarely reported. It may mimic leprosy and its differentiation may be difficult,
since both diseases may show hypo-pigmented macular lesions as clinical presentation and neural involvement in
histopathological investigations. The co-infection of leprosy and VL has been reported in countries where both
diseases are endemic. The authors report a co-infection case of leprosy and VL, which evolved into PKDL and
discuss the clinical and the pathological aspects in the patient and review the literature on this disease.
Case presentation: We report an unusual case of a 53-year-old female patient from Alagoas, Brazil. She presented
with leprosy and a necrotizing erythema nodosum, a type II leprosy reaction, about 3 month after finishing the
treatment (MDT-MB) for leprosy. She was hospitalized and VL was diagnosed at that time and she was successfully
treated with liposomal amphotericin B. After 6 months, she developed a few hypo-pigmented papules on her
forehead. A granulomatous inflammatory infiltrate throughout the dermis was observed at histopathological
examination of the skin biopsy. It consisted of epithelioid histiocytes, lymphocytes and plasma cells with the
presence of amastigotes of Leishmania in macrophages (Leishman’s bodies). The diagnosis of post-kala-azar dermal
leishmaniasis was established because at this time there was no hepatosplenomegaly and the bone marrow did
not show Leishmania parasites thus excluding VL. About 2 years after the treatment of PKDL with liposomal
amphotericin B the patient is still without PKDL lesions.
Conclusion: Post-kala-azar dermal leishmaniasis is a rare dermal complication of VL that mimics leprosy and should
be considered particularly in countries where both diseases are endemic. A co-infection must be seriously
considered, especially in patients who are non-responsive to treatment or develop persistent leprosy reactions as
those encountered in the patient reported here.
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Background
Post-kala-azar dermal leishmaniasis (PKDL) is a rare
skin disease, which may occur after treatment of visceral
leishmaniasis (VL) and is encountered mainly in India
and in the Sudan, where it was also reported to occur
during active VL. It has rarely been reported in the
South American literature. It is associated with an
inadequate immune response to Leishmania and a pos-
sible genetic predisposition. It may mimic leprosy clinic-
ally with hypo-pigmented macular lesions usually on the
face. Histopathological differentiation may be very diffi-
cult because both diseases, particularly in the Sudan,
may show neural involvement. Co-infection has been
reported in countries where both leprosy and VL are en-
demic and should be considered when there is a poor
response to treatment or when persistent leprosy
reactions occur [1].
* Correspondence: angelatrindade@uol.com.br
1Laboratório de Investigação Médica (LIM-56), Imunodermatologia, Hospital das
Clínicas da Universidade de São Paulo, Dr Enéas Carvalho Aguiar 470, 3 andar,
prédio 2 Instituto de Medicina Tropical, São Paulo 05403900, Brazil
2Departamento de Dermatologia, Faculdade de Medicina da Universidade de
São Paulo, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2015 Trindade et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Trindade et al. BMC Infectious Diseases  (2015) 15:543 
DOI 10.1186/s12879-015-1260-x
Case presentation
The patient was a 53-year-old woman who had migrated
to São Paulo city, Brazil from Arapiraca, Alagoas in the
Northeast of Brazil. She visited the dermatology out-
patient department of the University of São Paulo
Medical School Hospital (HCFMUSP) with complaints
of fever and skin lesions that had persisted for over a
year and had worsened during the last 3 months. She
mentioned that she had been treated for leprosy (MDT-
MB) for 14 months, which had ended 3 months earlier.
She had used prednisone intermittently for over a year
during outbreaks of reactions.
Dermatological examination showed a Cushingoid
face, widespread erythematous and edematous, some
painful plaques and nodules some of which with central
necrosis. This led us to establish the diagnosis of sub-
polar lepromatous leprosy (LLsp) with a necrotizing
erythema nodosum leprosum (ENL) reaction (type-2
leprosy reaction) (Fig. 1).
She was many times hospitalized during the 3 years
after MDT-MB and once in a critical condition with
fever, tachycardia and hypotension. Prednisone 40 mg/
day and thalidomide 300 mg/day were prescribed at the
intensive care unit for treating the reaction. During
hospitalization, the patient developed a septic shock.
The skin was considered the most likely focus and she
was treated with oxacillin.
After 6 days, despite general clinical improvement, the
skin lesions worsened, but no other focus of infection
was found. Histopathological examinations of the skin,
one from a biopsy of the right cavum plantaris and one
from a biopsy of the left arm were conducted. Both of
them showed multi-bacillary leprosy with a regressive
response and fragmented acid-fast bacilli (2+/6+).
After a few days, the patient had new fever attacks,
swelling of the abdomen, generalized edema and
worsening of the necrotizing ENL. She had elevated
levels of liver enzymes, pancytopenia with progressive
hypotension, hepatic and hematologic failure. Empir-
ical antibiotic therapy with vancomycin and imipenem
indicated by the infectious disease department was
started. Liposomal amphotericin B was also intro-
duced to cover the possibility of fungemia or candide-
mia (the patient had an esophageal candidiasis
diagnosed by endoscopy, supposedly due to the long-
term corticosteroid therapy).
Fig. 1 Erythema nodosum leprosum (ENL). a and b Clinical aspects of ENL episode. c to f Biopsy from skin lesion displaying nodular macrophage
infiltrate (c and d), vascular thrombosis (e) and foci of neutrophils exudation (f)
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Three days later, a new investigation at the emergency
department showed hepatosplenomegaly and ascites. VL
was diagnosed based on the parasitology of the bone
marrow (Fig. 2a), the gold standard for diagnosis of VL
and on blood examinations, which showed numerous
intracellular and extracellular Leishmania parasites;
using rk39 (39 amino acid repeats of a kinesin-like gene
found in L. chagasi), a rapid immunochromatographic
test specific for the Leishmania donovani complex [2]
and by molecular tests (kDNA-PCR = kinetoplast target
DNA for PCR and ITS1-DNA-PCR = Internal
Transcribed Spacer 1 target DNA for PCR). In addition,
after ITS1-RFLP (PCR amplification of the Internal
Transcribed Spacer 1 genes (ITS1) and Restriction
Fragment Length Polymorphism) (Fig. 2b), fitted-in with
the diagnosis of VL, it was demonstrated definitively
that L. (L.) infantum chagasi was the etiologic agent, be-
cause it presented 184 bp (base pair), 72 and 55 bp
fragments [3].
Liposomal amphotericin B (4 mg/kg/day for 5 days)
was now continued for the treatment of VL (kala-azar).
This also led to a significant clinical improvement of her
ENL skin lesions. Secondary prophylaxis with amphoter-
icin B (3 mg/kg/day for 21 days each month during
6 months) was introduced by the infectious diseases
physicians. During the last dose only the kDNA-PCR
with her blood was positive.
Around 6 months after the treatment for VL and free
of necrotizing ENL for 1 year and an occasional nodule
of ENL, she developed a few hypochromic papules on
her forehead (Fig. 3a). Histopathological examination of
a biopsy of such a papular lesion showed a granuloma-
tous inflammatory infiltrate throughout the dermis and
superficially in the sub-cutis consisting of epithelioid his-
tiocytes, lymphocytes and many plasma cells (Fig. 3b).
Leishman bodies were seen within macrophages (Fig. 3c).
The presence of Leishmania was further confirmed by
immunohistochemistry (Fig. 3d) using a peroxidase-anti-
peroxidase technique and a polyclonal antibody to
Leishmania produced in rabbits [4]. At this time, there
was no hepatosplenomegaly and the bone marrow did
not show Leishmania parasites. A revision of all previous
skin biopsies with immunohistochemistry for
Leishmania was performed, but the results were all
negative. At that moment, the diagnosis of post-kala-
azar dermal leishmaniasis (PKDL) was established and
liposomal amphotericin B (3 mg/kg/day for 7 days) was
re-introduced resulting in a clinical regression of the
skin lesions that was confirmed by histopathological ex-
aminations. About 2 years after the treatment of PKDL
the patient is still free of PKDL lesions.
Discussion
Post-kala-azar dermal leishmaniasis is a dermal compli-
cation of VL [5], which has been frequently reported
from the Indian subcontinent and from the Sudan,
where 10–20 % and 50–60 % respectively, of the patients
who were treated for VL developed PKDL [6, 7]. In
Brazil, only one patient with PKDL was reported and
this was associated with AIDS [8].
Visceral leishmaniasis has a worldwide distribution
and is considered a public health problem in 88 coun-
tries, including Brazil [9]. It is caused by species of the
Leishmania donovani complex, transmitted by the bite
of a female sand fly (Phlebotomus spp and P. argentipes)
[6, 10]. In Latin America, the main causative agent of
VL is Leishmania (L) infantum chagasi transmitted by
Lutzomiya longipalpis [11, 12]. In Brazil, asymptomatic
infections and mild forms (low symptomatic) of the dis-
ease are more frequent than the classic VL (Kala-azar)
[13]. The asymptomatic forms occur especially in chil-
dren and may heal spontaneously. The determinant
factor in spontaneous healing or evolution to fatal classic
disease is malnutrition [14].
The symptomatology of kala-azar reactivation in im-
munosuppressed patients is very variable depending on
the type and the duration of immunosuppression (trans-
plantation or autoimmune disease), or the time and the
duration of immunosuppression by HIV and others dis-
eases [15]. The clinical forms of VL, particularly in these
conditions are very variable. In general, the classic
Fig. 2 Leishmania identification. a Smear from patient myelogram
displaying amastigotes of Leishmania within macrophage cytoplasm
(arrows). b Identification of L infantum (184, 72 and 55 bp) in clinical
material from a patient (sample 31) using ITS1-PCR-RFLP
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symptoms such as bowel and gastric dysfunctions are
not highlight to the diagnosis [16, 17].
In India, the human being is the only known reservoir
of VL. This is of epidemiological importance, particularly
between epidemic periods of VL. The Leishmania para-
sites survive and propagate intradermally rendering the
exposed skin lesions as an easy access area for the sand
fly vector to ingest Leishmania parasites, get infected
and develop the promastigotes in their midgut enabling
them to transmit the parasite. The presence of only
0.5 % of PKDL patients during a VL epidemic can poten-
tially succeed in making VL endemic [10]. In other areas
such as the Sudan, transmission may be anthroponotic
and zoonotic, with rodents and canines as candidate res-
ervoirs [18]. In Brazil, VL is zoonotic with canines as the
reservoir host [6].
The causative agent of PKDL in the Sudan and on the
Indian subcontinent belongs to the L. donovani sp. Of
these species L. (L) infantum chagasi was also found in
the skin lesions of Brazilian patients with VL [19]. In
Europe and in South America, PKDL may be considered
to be a rare clinical entity among Aids patients with L.
infantum as the prime causative agent [20]. The same
species was also found in the patient reported here.
Post-Kala-azar dermal leishmaniasis may develop dur-
ing or after treatment of VL [6, 21]. However, some pa-
tients have no history of VL and they are easily
misdiagnosed as having other skin disorders [18]. In the
Sudan, the PKDL cases occur 60 % after VL treatment,
15 % at the same time as VL (called paraKDL), and 10 %
even without a history of VL [22]. Indian PKDL appears
6–12 months after the cure of VL [5], whereas in the
majority of the Sudanese patients, PKDL occurs within
the first 2 months following treatment of VL [23]. It was
also reported in HIV/VL co-infected patients receiving
HAART [21]. Our patient developed PKDL 6 months
after the end of VL treatment, similar to that reported in
the Indian patients.
Possible risk factors for developing PKDL include pre-
vious VL treatment, its duration and the type of drug
used, young age, malnutrition, HIV infection, genetic
factors and the parasite strain [24]. Parasite clearance
during treatment may have an important influence.
Zijlstra et al. [6] reported that patients with a negative
tissue aspirate (lymph node or bone marrow) on PCR
after VL treatment did not develop PKDL, whereas 36 %
of those who were PCR-positive developed PKDL. The
patient reported here was PCR-positive in the 4th month
of treatment for VL. The presence of a large spleen dur-
ing VL was also linked to an increased risk of PKDL as
were the high serum levels of C-reactive protein as seen
in our patient too (data not shown) before treatment for
VL, the high level of IL-10 in the peripheral blood and
in the normal looking skin during VL [6, 20, 25, 26].
Among all these, incomplete or short treatment of VL
seems to be the major risk factor [20]. Our patient had
received liposomal amphotericin B (4 mg/kg/day) during
5 days to treat her VL as recommended by the Ministry
of Health in Brazil [27] with clinical improvement in few
days.
It was argued that after VL treatment there was a sub-
sequent immune activation that could force the parasites
Fig. 3 Post-kala-azar dermal leishmaniasis. a Hypochromic papule in the forehead. b The skin biopsy showed dermal nodular granulomatous
infiltrate. c Few amastigotes of Leishmania were observed within macrophage cytoplasm (arrow) intermingled in the lymph plasmacytic infiltrate.
d The parasites were visible better after staining with anti-Leishmania polyclonal antibody
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to seek refuge within the dermis making this tissue a
reservoir for the parasites [10]. Despite the demonstra-
tion of PKDL after inadequate therapy for VL in the
Sudan, many authors reported PKDL even after ad-
equate treatment with sodium antimony gluconate
(SAG), amphotericin B and miltefosine [28, 29]. Today,
PKDL is no longer considered to be a specific drug-
dependent manifestation [20].
Post-Kala-azar dermal leishmaniasis is clinically
characterized by hypo-pigmented macules, erythema-
tous plaques, papular or nodular lesions with Leish-
mania parasites [5, 30]. The lesions generally begin
on the face and gradually increase in size. They may
also spread to the neck, the trunk and the extremities
[10]. Papular or nodular lesions are more common in
the Sudanese PKDL, whereas a polymorphic presenta-
tion with macules, papules and nodules is more com-
mon in the Indian patients [6, 31, 32]. Unusual
clinical variants such as papillomatous, verrucous,
hypertrophic, xanthomatous, annular and lupoid le-
sions have also been reported [33, 34]. Mucosa
involvement in PKDL is very rare [35]. No constitu-
tional symptoms have been reported [36].
Although clinical forms may differ in different coun-
tries, the hypopigmented macules on the face are gener-
ally the first lesions to appear in PKDL. Single lesion
occurs in up to 5 % and 10 % respectively, of the PKDL
cases in Africa and India [30, 37]. Our patient presented
with only a few hypopigmented papules on her forehead
as the unique manifestation of the disease.
The diagnosis is established after assessing the clinical
signs and symptoms [38]. History of VL, living in an en-
demic area and positive antibody tests are helpful in the
diagnosis [20, 38]. According to Zijlstra et al. [6], it is
important to observe the type of rash as well as its dis-
tribution (in the Sudan, the rash generally begins around
the mouth, then spreads to the nose and the cheeks and
finally to other parts of the face and the body) and the
time relation to VL treatment. However, the ideal diag-
nostic method is to demonstrate the parasite in smears,
culture or PCR [18, 20].
In all clinical types of PKDL, histopathological examin-
ation of the skin biopsy shows an epidermis with hyper-
keratosis, acanthosis or atrophy and hydropic
degeneration of the basal layer. The presence of parasites
in biopsies varies with the type of the rash and the dur-
ation of the lesions. The biopsy from macular lesions
usually consists of sparse inflammatory infiltrate of lym-
phocytes, histiocytes and a few plasma cells predomin-
antly around the vessels of the superficial vascular
plexus. Leishmania amastigotes are usually absent in
such lesions, but the presence of plasma cells is an im-
portant clue in favor of PKDL. Biopsies from the papules
and plaques show a moderate to dense lymphocytic
inflammatory infiltrate in the mid-dermis, with histio-
cytes and plasma cells. In nodular lesions, the histo-
pathological examination of the biopsy shows a diffuse
dermal inflammatory infiltrate consisting of histiocytes
and plasma cells in large numbers. Compact epithelioid
granulomas may also be observed [6].
The Leishmania amastigotes are intracytoplasmic
structures in histiocytes. Amastigotes are observed in
25–50 % of the hematoxylin-eosin-stained biopsies of
nodular and plaque lesions of PKDL [39, 40]. In the pa-
tient reported here, the papular lesion had Leishmania
amastigotes, which was also confirmed by immunohisto-
chemistry with an anti-Leishmania polyclonal antibody.
Neuritis involving small cutaneous nerves similar to
that in leprosy was reported in PKDL. However, periph-
eral large nerves are not involved in PKDL [6, 36].
Leprosy is the main differential diagnosis in PKDL
because of the clinical and histopathological similar-
ities [30], but their differentiation may be very diffi-
cult [36, 41, 42]. The small hypopigmented lesions
seen in PKDL are very similar to those in borderline
and lepromatous leprosy [30, 41]. The patients with
leprosy and PKDL usually come from the same geo-
graphical location where both diseases are endemic
[5]. However, leprosy is associated with hypoesthetic
lesions [22]. Arora et al. reported that the center-
facial involvement and the sparing of ear lobes in
PKDL may be distinguishing features from leprosy
[5]. Histologically, PKDL displays epithelioid cell
granulomas, similar to tuberculoid leprosy. The para-
sites may be absent in the macular variant of PKDL
making it essential to exclude other diseases [30].
Perineural infiltration in PKDL was reported to cause
great difficulty in differentiating PKDL from leprosy
[30, 35]. However, the main histological difference be-
tween these diseases is that in the macular lesions of
leprosy, the inflammatory infiltrate is centered in the
neurovascular plexus in the lower dermis. Besides
this, in the nodular lesions of lepromatous leprosy,
the peripheral limits of the infiltrate are infiltrative,
whereas those in nodular PKDL have a fairly sharp
margin [30].
Leprosy and leishmaniasis are both spectral diseases
and co-infections have been reported. Although it is a
rare association, it occurs in countries such Ethiopia and
India where both diseases are endemic [42]. The case re-
ported here of co-infection with PKDL is the first in
Brazil.
Leishmaniasis and leprosy share a lot of similarities.
Both diseases are caused by obligate intracellular organ-
isms. The clinical and pathological expressions depend
on the host response, probably due to genetic determin-
ation and environmental influences [42, 43]. At the
hyperergic pole, the patient shows localized lesions with
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well-formed granulomas with few or absent organisms,
whereas at the anergic pole, the lesions are widespread,
there is no epithelioid granulomatous reaction and there
are numerous parasites [42].
It was suggested by Bansal et al. that there is a cross-
protection between Mycobacterium and Leishmania
infection since both diseases increase macrophage acti-
vation. However, the immune deficiency in leprosy is ap-
parently specific for M. leprae only and does not dictate
the immune response in leishmaniasis. They reported a
patient in whom the macular variant of PKDL (‘low-re-
sistance’) coexisted with ‘high-resistance’ borderline tu-
berculoid leprosy [42]. Our patient presented subpolar
lepromatous leprosy with a VL co-infection considered
as an anergic pole of both diseases (Th2 response). After
developing PKDL, the immunological response changed
to the hyperergic pole (Th1 response) of the Leishmania
infection, when she showed papules with epithelioid
granulomas, but she remained at Th2 pole of leprosy in-
dicating that the immune defect was specific for each
microorganism [42, 43].
To date, there is no consensus and no large studies on
the best available treatment for PKDL. Moreover, the evo-
lution of this disease differs in different geographical re-
gions. Fifty per cent of the Sudanese PKDL is self-limiting
and heal spontaneously, whereas all Indian PKDL cases
required treatment [6, 20, 33]. In cases of severe lesions or
lesions persisting for more than 1 year in the Sudan, treat-
ment with sodium stibogluconate (SSG) 20 mg/kg/day for
1–2 months was instituted [6, 10]. Miltefosine adminis-
tered orally was an effective and safe treatment for Indian
visceral leishmaniasis. It may protect against PKDL be-
cause it is given for a much longer period. It may be help-
ful in regions where the parasites are resistant to the
current agents [15, 44].
In cases of SSG-unresponsive treatment, amphotericin
B 2 mg/kg/day for 20 days was reported to be effective
[6, 10, 20]. Other therapeutic options include miltefo-
sine, ketoconazole and pentamidine [6, 10]. Clinical cure
may differ according to the PKDL type. Usually nodules
and plaques disappear in 120 days and macular lesions
in 200 days [6, 10]. However, parasitological cure may
precede the clinical cure, and long treatment regimens
need to be carefully monitored [6]. Our patient received
liposomal amphotericin B (3 mg/kg/day for 7 days), with
clinical healing of the skin PKDL lesions in 3 months.
At this moment the patient is in good health and with-
out skin lesions indicative of PKDL. She has only regres-
sive macules of leprosy. However, at present she
received the 10th dose of a newly started MDT-MB
treatment because she had the first symptoms of tibial
neuritis about 5 year after leprosy treatment. It is likely
that the previous treatment for 14 months may have
been inadequate.
Conclusions
Post-kala-azar dermal leishmaniasis is rare and generally
occurs after treatment of VL. It shows geographical vari-
ation in its clinical presentation and may be multifactor-
ial (genetics of the patient and or parasite, treatment,
nutrition and or co-infection). It may mimic leprosy and
that must be recognized, especially in countries where
these diseases are endemic. Increasing globalization with
large number of people travelling should also be ser-
iously considered.
A co-infection may provoke more morbidity and may
also lead to more disability. A co-infection should be
considered especially in patients not responding to treat-
ment or have a persistent leprosy reaction similar to that
described in the patient reported here.
Finally we introduce a serious concern: Visceral leish-
maniasis will be able to become an anthropozoonosis in
the Americas, like in India (15), because, before and dur-
ing PKDL, the parasite will be exposed in the skin.
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